LEVERAGING ARTIFICIAL INTELLIGENCE.

Imagine a future where groundbreaking therapies emerge faster, targeting diseases with precision once thought unattainable. At Tecan, we make that vision a reality by combining artificial intelligence (AI) with the power of wet-lab validation to create synergy that transforms the pharmaceutical research landscape.

AI-driven in-silico models redefine the speed and scope of drug discovery, predict molecular interactions, and uncover potential therapeutic targets. These digital innovations provide the foundation for high-throughput drug screening and focus research on the most promising candidates. Yet even the most sophisticated AI predictions require validation through wet-lab experiments. Lab automation delivers the reproducible, high-quality data that AI demands—data that manual processes simply cannot provide.

Tecan’s advanced automation tools and consumables ensure these critical validations are performed efficiently, with precision and scalability. By integrating AI-driven predictions with empirical wet-lab testing, pharmaceutical innovators can streamline the drug discovery pathway. This dual approach reduces costly failures in later stages, accelerates development timelines, and unlocks deeper insights into complex biological pathways.

One example of this synergy is in the exploration of treatments for diseases with limited options, such as rare genetic disorders or advanced oncology. AI helps identify potential drug targets faster, while Tecan’s automation solutions optimize the experimental workflows needed to confirm efficacy and relevance. The result is a more focused and reliable drug development process that minimizes risk while maximizing impact.

Advancing this integration is not just a technological leap– it’s a commitment to better science. With Tecan’s support, pharmaceutical researchers can ensure that every therapeutic candidate is backed by robust empirical evidence, propelling the industry toward faster, more reliable, and life-changing discoveries.